Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.33 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | HINT1 | P49773 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16214171 | 0.89 | ADORA3 (0.47) | ADORA3HINT1NT5EHPRT1 | |
| SCHEMBL16866666 | 0.83 | ADORA3 (0.42) | ADORA3HINT1NT5EHPRT1 | |
| SCHEMBL15070832 | 0.79 | ADORA3 (0.37) | ADORA3HPGDIMPDH2IMPDH1TAS1R3 | |
| SCHEMBL18022452 | 0.79 | HPGD (0.39) | ADORA3HPGDIMPDH2IMPDH1TAS1R3 | |
| SCHEMBL18022450 | 0.78 | HPGD (0.42) | ADORA3HPGDIMPDH2IMPDH1TAS1R3 | |
| SCHEMBL15837496 | 0.76 | ADORA3 (0.39) | ADORA3HPGDIMPDH2IMPDH1TAS1R3 | |
| SCHEMBL15837259 | 0.76 | ADORA3 (0.39) | ADORA3HPGDIMPDH2IMPDH1TAS1R3 | |
| SCHEMBL16214187 | 0.75 | CYP3A4 (0.46) | IMPDH2TAS1R3TAS1R1 | |
| SCHEMBL16214152 | 0.75 | POLG (0.47) | NT5EHPRT1 | |
| SCHEMBL16214109 | 0.75 | ADORA3 (0.39) | ADORA3HINT1NT5EHPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264610-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-9346848-B2 | Azido nucleosides and nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150183819-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2015-07-02 | — | — | US | disclosed |
| US-8877731-B2 | Azido nucleosides and nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264610-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | ADORA3 20/4885HPGD 1203/4885IMPDH2 91/4885 |
| US-20150183819-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | ADORA3 20/4885HPGD 1203/4885IMPDH2 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.